Abhi International Journals of Biological Science (AIJBS)
ISSN(online): ……..
Vol. 2, Issue. 1, January 2025

Investigating the Role of Gut Microbiome Metabolites in Diabetic Chronic Kidney Disease

Sanat Sharma

NIET, NIMS University, Jaipur, India

ARTICLE INFO

Article History:
Received December 15, 2024
Revised December 30, 2024
Accepted January 12, 2025
Available online January 25, 2025

Keywords:

Correspondence:
E-mail:
jangidsanat0@gmail.com

ABSTRACT

Gut microbiome metabolites play a very complex role in the progression of Diabetic Chronic Kidney Disease, with the necessity to understand the mechanistic pathways connecting these metabolites with kidney health. This article discusses the five critical points: the role of gut microbiota in the formation of DCKD-related metabolites, host genes being targeted, mechanistic pathways involved, microbial species and DCKD, and therapeutic potential of such an interaction. Utilizing computational models and enrichment analyses, findings confirm the significant role of specific metabolites such as 3-Indole propionic acid and microbial species like F. prausnitzii in mitigating DCKD progression. These metabolites modulate disease pathways, particularly the MAPK/NF-KB1 signaling, showcasing potential therapeutic applications. This research bridges gaps in understanding the gut-kidney axis and emphasizes the need for experimental validation to advance microbiome-targeted interventions for DCKD management.

Introduction

This section delves into the intricate interplay between gut microbiome metabolites and diabetic chronic kidney disease, underlining the necessity of understanding the mechanistic pathways by which kidneys sense these metabolites. The core research question addresses how gut microbiome metabolites impact DCKD, focusing on five sub-research questions: the role of gut microbiota in producing metabolites affecting DCKD, the identification of host genes targeted by these metabolites, the mechanistic pathways of metabolite action, the impact of specific microbial species on DCKD, and the therapeutic potential of targeting these pathways. The study is a quantitative one and focuses on microbial species, metabolites, host genes, and the progression of DCKD. The paper is organized to include a literature review, methodology, findings, and discussion on the relevance of the study in understanding and possibly treating DCKD.

Literature Review

This section reviews the available literature on the gut-kidney axis, and their implications on DCKD, directed by the five sub-research questions: metabolites production by gut microbiota, host gene targeting by these metabolites, mechanistic pathways of action, microbial species impacting DCKD, and therapeutic implications. Gaps in the understanding of the mechanisms were identified and suggestions were made to the kind of research that needs to be conducted in order to fill those gaps based on a hypothesis for every sub-research question.

Gut Microbiota and Metabolites

The gut microbiota of early studies produces a wide array of metabolites with potential implications in host health. Those early studies had catalogued this metabolite universe without further studying their specific contribution to DCKD. It took later studies, which started pinpointing associations with kidney function-related metabolites without detailed mechanistic

understanding, to get these studies going forward. New studies seek to identify the pathways involved but fail to clarify the mechanisms and imp5lications of metabolite production on DCKD. Hypothesis 1: There exist specific gut microbiota, and the metabolites they produce have a crucial role on DCKD progression.

Host Gene Targeting by Metabolites

Initial studies discovered that the gut-derived metabolites could potentially alter host gene expression, mainly through broad correlation studies. Studies have had poor resolution in identification of genes targeted in DCKD. More recent studies have sought to associate specific metabolites with gene targets, but this has often been made in a manner that lacks robust validation. The latest studies utilize advanced bioinformatics for target gene prediction, but experimental validation remains rudimentary. Hypothesis 2: Gut-derived metabolites specifically target host genes critical to DCKD pathogenesis.

Mechanistic Pathways of Metabolite Action

Early studies focused on general pathways by which metabolites could affect disease, often using theoretical models. These studies provided a foundation but lacked experimental evidence to link specific pathways to DCKD. As research advanced, more detailed pathway analyses appeared, but they often relied on indirect evidence. Current studies are using computational models to predict pathways but still require empirical validation. Hypothesis 3: Metabolites from gut microbiota modulate DCKD progression through specific mechanistic pathways, particularly involving MAPK/NF-KB1 signalling.

Impact of Microbial Species on DCKD

Initial studies revealed some species to be linked to general health status, while those with DCKD-specific correlations were under-studied. Successive studies further began associating certain species with kidney functions; however, their mechanisms remained vague. Recent studies on DCKD have mainly shifted to understanding specific microbes involved, while complete mechanistic studies are not yet performed. Hypothesis 4: Some species are directly implicated in the progression of DCKD via the metabolite production of that species.

Therapeutic Potential of Targeting Pathways

Early drug discovery was based on universal intervention rather than pathway-specific therapy. As the relationship between gut and kidneys became better understood, researchers began to make suggestions for targeted therapy but most of them were not validated in the clinic. Studies are currently carried out on real-time modulation of specific pathways for therapeutic benefit. Hypothesis 5: Targeting specific gut-derived metabolic pathways offers therapeutic potential in managing DCKD.

Method

This section discusses the quantitative research methodology applied in investigating the hypotheses. It includes sources of data, selection of variables, and computational analyses. The results are grounded in sound data collection and analysis.

Data

Data for this study are derived from several databases such as gutMgene, PubChem, DisGeNET, Gene Card, NCBI, and OMIM. Data sources include microbial metabolites, host-targeting genes, and DCKD targets. Data collection involves isolation of relevant metabolites and genes, followed by computational analysis to ascertain interactions and pathways. The sampling method includes database selection that should provide comprehensive gut microbiome coverage and DCKD. Criteria for screening included focusing on metabolites and genes which have established relevance to DCKD, making sure that this dataset is sound for analysis.

Variables

Variables analyzed are many: the independent variables being species of gut microbiota, its metabolites, host gene expression, and the course of DCKD, and instrumental variables-computational models of networks while the control variables involved are demographic factors as well as basic diseases among the patients. Variable selection as well as processing follows a literature study validated by experiment ensuring reliable measurements of the method adopted. Literature from Network analyst, ShinyGo, and Auto dock tools is used to validate variable reliability. The analysis uses protein-protein interaction networks, enrichment pathways, and molecular docking to explore these relationships.

Results

The results start with a descriptive statistical analysis of microbial metabolites, host genes, and DCKD targets. The results confirm all of the five hypotheses: Hypothesis 1 is confirmed in showing that gut microbiota produce specific metabolites that significantly affect DCKD progression; Hypothesis 2 reveals the identified host genes targeted by these metabolites; Hypothesis 3 confirms modulation of DCKD via MAPK/NF-KB1 signalling pathways; Hypothesis 4 gives evidence for the direct impact of specific microbial species toward DCKD; and Hypothesis 5 shows the potential of a therapy through targeting these pathways. The results demonstrate the intricate interaction between the gut microbiota and renal health and thereby indicate possible avenues for therapy.

Sub-Gut Microbiota and Metabolite Effects on DCKD

This result verifies Hypothesis 1 in that certain gut microbiota cause distinct metabolites to have a great influence on the progression of DCKD. Independent variables arising from a number of 574 microbial metabolites are reportedly the microbial species F. parasitize, B. adolescents, and B.distasonis. Dependent variables are the markers for DCKD progression. The results indicate that these microbes produce specific metabolites like 3-Indole propionic acid (IPA) exhibiting their association with reduced DCKD progression, and showing high binding energy affinity to -5.9 kcal/mol and -7.4 kcal/mol. This empirical significance would mean that some microbial metabolites have protective effects against DCKD and is being aligned with theories of microbial-host interaction and disease modulation. This finding underlines the potential of microbiome-based interventions in the management of DCKD by filling gaps in understanding the microbial production of protective metabolites.

Host Genes Targeted by Metabolite in DCKD

This finding supports Hypothesis 2, which states that gut-derived metabolites target certain host genes essential for the development of DCKD. From an analysis of 2861 DCKD targets and 222 microbial host-targeting genes, the findings pointed out substantial interplays between the metabolites and host genes in NF-KB1, AKT1, EGFR, JUN, and RELA. Independent variables include particular metabolites, but dependent variables consist of host gene expression. Thus, there is correlation between metabolites regulating gene expression toward the progression of DCKD. The empirical significance reinforces theories on metabolite-gene interactions, highlighting that targeted metabolites can influence disease pathways. By addressing gaps in identifying gene targets, this finding emphasizes the importance of understanding metabolite-gene interactions in DCKD treatment strategies.

Mechanistic Pathways Modulating DCKD

This finding validates Hypothesis 3, positing that metabolites from gut microbiota modulate DCKD progression through specific mechanistic pathways, particularly involving MAPK/NF-KB1 signaling. The significant pathways influenced by the metabolites were identified by applying computational models along with enrichment pathway data. Metabolites, for example 3-Indole propionic acid, represent major independent variables; the dependent variable consists of pathway activity. The empirical implication is that such metabolites prevent inflammatory pathways, and hence reduce DCKD progression. Targeted therapeutic interventions are thereby possible, which

could arise from an understanding of such pathways. This finding has the potential to target specific signalling

pathways in DCKD management by filling gaps in pathway identification.

Microbial Species Influence on DCKD Progression

This finding supports Hypothesis 4, which suggests that some microbial species directly influence DCKD progression through metabolite production. The analysis uses data from microbial species and DCKD progression markers to identify species such as F.prausnitzi, B.adolescentis, and B.distasonis as significant contributors. Independent variables include microbial species, and dependent variables focus on DCKD markers. The findings are that such species produce metabolites that have positive effects on kidney health. Empirical significance is that knowledge of microbial contributions could inform probiotic therapies. In filling gaps in studies of the impact of microbes, this finding underlines the potential of microbiome-targeted interventions in DCKD.

Therapeutic Potential of Targeting Metabolic Pathways

This conclusion proves Hypothesis 5 by highlighting the therapeutic potential of specific gut-derived metabolic pathways in managing DCKD. It analyses the therapeutic benefits derived from targeting metabolites such as 3-Indole propionic acid on specific pathways. Key independent variables used here are the targeted pathways, whereas dependent variables center around the therapeutic benefits. The conclusion implies that intervention by targeting such pathways could retard DCKD progression. The empirical significance suggests that pathway-targeted therapies may open up new avenues for the treatment of DCKD. This finding, by filling gaps in therapeutic research, emphasizes the potential of metabolic pathway modulation in the management of DCKD.

Conclusion

This study collates findings on the impact of gut microbiome metabolites on DCKD, emphasizing their roles in modulating disease progression through specific pathways and microbial species. The research underscores the potential of microbiome-based interventions in managing DCKD. However, the calculated data and models could only partially represent the real scenario in the system because they could not consider the complexity of a real system. Future research should be conducted to confirm the results with experimental studies and involve additional species of microbes and their metabolites to improve treatment strategy. Addressing these areas would provide future researchers with a more accurate understanding of the gut-kidney axis in DCKD.

References

[1] Jandhyala, S. M., Talukdar, R., Subramanyam, C., et al. (2015). Role of the normal gut microbiota. *World Journal of Gastroenterology, 21*(29), 8787-8803.

[2] Kim, D. H. (2015). Gut microbiota-mediated drug-antibiotic interactions. *Drug Metabolism and Disposition, 43*(10), 1581-1589.

[3] Xu, X., Gao, J., Han, J., et al. (2019). The role of gut microbiota in kidney disease development and progression. *Frontiers in Physiology, 10*, 492.

[4] Nicholson, J. K., Holmes, E., Kinross, J., et al. (2012). Host-gut microbiota metabolic interactions. *Science, 336*(6086), 1262-1267.

[5] Kobayashi, M., Mikami, D., Kimura, H., et al. (2020). Gut microbiota as a potential therapeutic target in chronic kidney disease. *Nephrology Dialysis Transplantation, 35*(6), 943-950.

[6] Wang, Z., Klipfell, E., Bennett, B. J., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature, 472*(7341), 57-63.

[7] Vaziri, N. D., Wong, J., Pahl, M., et al. (2013). Chronic kidney disease alters intestinal microbial flora. *Kidney International, 83*(2), 308-315.

[8] Holmes, E., Kinross, J., Gibson, G. R., et al. (2012). Therapeutic modulation of microbiota-host metabolic interactions. *Science Translational Medicine, 4*(137), 137rv6.

[9] Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy

[10] Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014

[11] Hyperglycemia modulates redox, inflammatory and vasoactive markers through specific signaling pathways in cerebral endothelial cells: Insights on insulin protective action

[12] L., Craig, P.A., Crichlow, G. V., Dalenberg, K., Duarte, J.M., Dutta, S., Fayazi, M., Feng, Z., Flatt, J.W., Ganesan, S., Ghosh, S., Goodsell, D.S., Green, R.K., Guranovic, V., Henry, J., Hudson, B.P., Khokhriakov, I., Lawson, C.L., Liang, Y., Lowe, R., Peisach, E., Persikova, I., Piehl, D.W., Rose, Y., Sali, A., Segura, J., Sekharan, M., Shao, C., Vallat, B., Voigt, M., Webb, B., Westbrook, J.D., Whetstone, S., Young, J.Y., Zalevsky, A., Zardecki, C., 2023. RCSB Protein Data Bank (RCSB.org): delivery of experimentally-determined PDB structures alongside one million computed structure models of proteins from artificial intelligence/machine learning. Nucleic Acids Res. https://doi.org/10.1093/nar/gkac1077.

[13] GutMGene: a comprehensive database for target genes of gut microbes and microbial metabolites

[14] Gene variants in the NF-KB pathway (NFKB1, NFKBIA, NFKBIZ) and their association with type 2 diabetes and impaired renal function

[15] Kassie, T.D., Anagaw, T.F., Mazengia, E.M., Gelaw, S.S., 2023. Prevalence and predictors of chronic kidney disease among type 2 diabetic patients worldwide, systematic review and meta-analysis. Diabetol. Metab. Syndr. https://doi.org/10.1186/s13098-023-01202-x.